tizanidine has been researched along with Muscle Rigidity in 5 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
Muscle Rigidity: Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 7.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 3.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanabe, M | 2 |
| Hashimoto, M | 1 |
| Ono, H | 1 |
| Gazulla Abío, J | 1 |
| Benavente Aguilar, I | 1 |
| Capablo Liesa, JL | 1 |
| Meinck, HM | 2 |
| Ricker, K | 1 |
| Conrad, B | 2 |
| Kaneko, T | 1 |
| Tonohiro, T | 1 |
| Iwata, N | 1 |
5 other studies available for tizanidine and Muscle Rigidity
| Article | Year |
|---|---|
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines | 2008 |
[Progressive encephalomyelitis with rigidity responsive to gabapentin: a pharmacological update].
Topics: Amines; Antiparkinson Agents; Clonidine; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr | 2004 |
The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine.
Topics: Adult; Brain Stem; Clomipramine; Clonidine; Diazepam; Electromyography; Female; Humans; Muscle Rigid | 1984 |
The pharmacological properties of CS-722, a newly synthesized centrally acting muscle relaxant.
Topics: Animals; Clonidine; Decerebrate State; Dose-Response Relationship, Drug; Electroencephalography; Evo | 1992 |
Neuropharmacological investigations in the stiff-man syndrome.
Topics: Adrenergic Fibers; Central Nervous System Diseases; Clonidine; Diazepam; Female; Humans; Methampheta | 1986 |